MANGALAM34.88

Mangalam Drugs And Organics Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMLASAVINEETLABORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹55.2 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-6.684.51-43.08-43.08
Return on Assets-2.721.83-14.10-14.10
Return on Capital Employed1.6210.99-27.98-27.98
Return on Invested Capital1.018.44-14.57-16.19
Margins
EBITDA Margin4.7211.26-6.42-4.65
Operating Margin0.746.04-14.27-14.27
Incremental Operating Margin-32.7060.79
Pretax Margin-3.001.50-20.92-19.09
Net Income Margin-2.462.11-19.13-17.96
FCF Margin-3.007.04-3.33-3.33
Additional
Effective Tax Rate18.08-40.438.595.93
Sustainable Growth Rate-6.684.51-43.08-43.08
Incremental Operating Margin %-32.7060.79-4.59
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.